On September 17, 2021 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, a potent biological mediator, reported that Elizabeth Evans, PhD, Chief Operating Officer, is scheduled to present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit (Press release, Vaccinex, SEP 17, 2021, View Source [SID1234587895]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Vaccinex’s SIGNAL-AD trial, a Phase 1/2 trial of pepinemab in patients diagnosed mild Alzheimer’s Disease (AD), is actively enrolling individuals living with AD. In cancer, Vaccinex is currently enrolling patients with recurrent or metastatic head and neck cancer in the Phase 1/2 KEYNOTE B84 trial which is evaluating the effectiveness of a combination of pepinemab with Merck’s KEYTRUDA checkpoint inhibitor.
Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit
Presentation Date: Wednesday, September 22, 2021 at 10:45-11:25
More information on the Summit can be found here.
The presentation slides from the Summit will be made available here on the Vaccinex website, www.vaccinex.com, at the time of the presentation.